Skip to content

Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice

de Picciotto NE, Gano LB, Johnson LC, Martens CR, Sindler AL, Mills KF, et al. | Aging Cell | 2016 | Evidence: limited

Plain-language summary

Published 2016 in Aging Cell, this work by de Picciotto NE and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

  • Preclinical animal study in Aging Cell (2016) investigating NAD+/NMN pathway mechanisms
  • Findings inform translational rationale; not yet replicated in humans
  • Mechanistic data on tissue-specific NAD+ effects

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to science decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

← Back to research index